Four cases of acute manic episode (bipolar-l disorder), not responding to oral valproate or other mood stabilizer and neuroleptics were given injection valproate intravenously. Three out of 4 patients showed good response and tolerance to intravenous valporate.
INTRODUCTION
Valptoare has emerged as an efficacious medication in the management of acute manic episode and in the long-term maintenance therapy of bipolar mood disorder (Bowden et al., 1994; McElroy et al., 1996) .
Injection valproate is now available for intravenous use. When valproare is administered intravenously; the peak plasma concentration is reached faster, the hepatic first-pass metabolism is bypassed and the gastrointestinal disturbances are less common (Devisky et al., 1995) . Duggal et al, (2000) found intravenous valproate to be efficaceous in a case of schizoaffective disorder.
The report summaries the use of injection valptoate administered intravenously in 4 cases of acute manic episode (bipolar-I disorder) (APA, 1994).
The following protocol (Grunze er al., 1999) was used in all the 4 patients for administration of intravenous valproate. Dosage of the drug was decided empirically as per the following protocol and it was not based on the body weight of the patients.
Each ml of injection valproate contains 100 mg of valproic acid. At a time 250 mg of injection valproare (2.5 ml) diluted in 250 ml of normal saline was given to the patient in the form of slow infusion drip over a period of 1 hour. Blood pressure of die patients was monitored twice everyday during hospitalization, keeping in view the side effect of hypotension due to intravenous Valproate. Patients were also monitored for development of hypersensitivity to the drug.
CASE REPORT -I
A 50 year old female patient, suffering from bipolar-I rhiorder since 20 years, maintained on lithium, presented with acute manic episode and symptoms of hypothyroidism low pulse rate, odema face and feet. So lithium was stopped and she was started on carbamezapine. As she did not tolerate earbamazepine, she was switched to oral valproate, which was gradually increased to 1750 mg per day over a period or 3 weeks. Clozapine 200 mg per day was added, since no significant improvement was noted with valproate alone. When she did not show any improvement widi the presented with acute manic episode. As she did not respond to a course of lithium and halopetidol combination over a period of 2 weeks) she was administered a course ot 8 ECTs. Since this also was not very useful, tablet clozapine 200 mg per day was added. With this a substantial clinical improvement was observed. But on follow up visit, she complained of excessive sedation and incontinence of urine during sleep. Clozapine had to be reduced and stopped. But after stopping clozapine manic symptoms increased and so the patient was started on intravenous valproate as per the protocol mentioned above, in this patient also, after the 1st infusion on day-1, clinical assessment showed some improvement in patient's behavior. On day-5 a significant improvement in grandiosity was noted. By day-15 she was in complete remission. During the therapy she complained of nausea and had one episode of vomiting. At present she is well maintained only on 750 mg of oral valproare. (251) A 52 year old male patient, suffering from bipolar-I disorder since 25 years, had 6 episodes of mania in 2001 and so was considered as rapid cyeler. He was tried on various combinations of lithium, clozapine, olanzapine, lorazepam, thioridazine and had received a course of 10 ECTs with little improvement. So he was considered for intravenous valproate fherapy.
Like previous 2 patients, this patient also showed a substantial improvement in psychomotor agitation after the 1st infusion of valproate on day-1. By the 5th day a very significant improvement was observed clinically and almost complete remission was achieved by the day-9. At present patient is well maintained on 800 mg or oral valproate. This patient did not have any side-effects except minimal sedation.
CASE REPORT-4
A 16 year old female patient, suffering from bipolar-I disorder since 1 year was brought by her relatives with acute manic episode. She was treated with haloperidol, chlorpromazine, carbamazepine, oxcarbazepine, and a course of 6 ECTs over a period of 4 weeks. She had developed ataxia with carbamezapine and diplopia with *NILESH SHAH, SUJIT SHENOY, PRADNYA < * Correspondence oxcarbazepine. As she did not show any substantial improvement clinically and had adverse reactions to the mood stabilisers, she was considered for intravenous valproate therapy.
Unlike the previous 3 patients, in this patient, no improvement in symptoms was observed after the infusion on day-1 and even on day-5 there was only a minimal improvement. On day-6 Patient developed giddiness, ataxia and incoordination and so the therapy was discontinued.
DISCUSSION
Intravenous valproate therapy for acute manic episode seems to be a very useful option. Though there are no formal guidelines or criteria, developed for the use of intravenous vaiproate, One may prefer to use it for die patients who do not respond to oral valproate, or otiier mood stabilizers and antipsychotic medications. The onset of improvement is almost immediate and a substantial improvement is noticed within 5 days of the treatment. Most of die patients seem to tolerate this therapy well, diough some of them may have excessive sedation, nausea, vomitting or CNS side effects. While using this therapy, one needs to be careful as patients may develop hypotension or hypersenstrvity reaction. The positive :, Department of Psychiatry, LT.M. Medical clinical experience warrants a double-blind placebo controlled trial to confirm diese findings.
